These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 26825555

  • 1. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
    Najafi A, Sequeira V, Helmes M, Bollen IA, Goebel M, Regan JA, Carrier L, Kuster DW, Van Der Velden J.
    Cardiovasc Res; 2016 May 15; 110(2):200-14. PubMed ID: 26825555
    [Abstract] [Full Text] [Related]

  • 2. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T.
    J Mol Cell Cardiol; 2013 Oct 15; 63():189-98. PubMed ID: 23896226
    [Abstract] [Full Text] [Related]

  • 3. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F, Geertz B, Reischmann-Düsener S, Weinberger F, Eschenhagen T, Carrier L, Friedrich FW.
    J Physiol; 2017 Jun 15; 595(12):3987-3999. PubMed ID: 28090637
    [Abstract] [Full Text] [Related]

  • 4. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M, van der Velden J.
    Circ Res; 2013 May 24; 112(11):1491-505. PubMed ID: 23508784
    [Abstract] [Full Text] [Related]

  • 5. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.
    Flenner F, Friedrich FW, Ungeheuer N, Christ T, Geertz B, Reischmann S, Wagner S, Stathopoulou K, Söhren KD, Weinberger F, Schwedhelm E, Cuello F, Maier LS, Eschenhagen T, Carrier L.
    Cardiovasc Res; 2016 Jan 01; 109(1):90-102. PubMed ID: 26531128
    [Abstract] [Full Text] [Related]

  • 6. Cardiac Myosin-binding Protein C and Troponin-I Phosphorylation Independently Modulate Myofilament Length-dependent Activation.
    Kumar M, Govindan S, Zhang M, Khairallah RJ, Martin JL, Sadayappan S, de Tombe PP.
    J Biol Chem; 2015 Dec 04; 290(49):29241-9. PubMed ID: 26453301
    [Abstract] [Full Text] [Related]

  • 7. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F, Jungen C, Küpker N, Ibel A, Kruse M, Koivumäki JT, Rinas A, Zech ATL, Rhoden A, Wijnker PJM, Lemoine MD, Steenpass A, Girdauskas E, Eschenhagen T, Meyer C, van der Velden J, Patten-Hamel M, Christ T, Carrier L.
    J Mol Cell Cardiol; 2021 Aug 04; 157():77-89. PubMed ID: 33957110
    [Abstract] [Full Text] [Related]

  • 8. Cardiomyocyte PKA Ablation Enhances Basal Contractility While Eliminates Cardiac β-Adrenergic Response Without Adverse Effects on the Heart.
    Zhang Y, Wang WE, Zhang X, Li Y, Chen B, Liu C, Ai X, Zhang X, Tian Y, Zhang C, Tang M, Szeto C, Hua X, Xie M, Zeng C, Wu Y, Zhou L, Zhu W, Yu D, Houser SR, Chen X.
    Circ Res; 2019 Jun 07; 124(12):1760-1777. PubMed ID: 30982412
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice.
    Cazorla O, Szilagyi S, Vignier N, Salazar G, Krämer E, Vassort G, Carrier L, Lacampagne A.
    Cardiovasc Res; 2006 Feb 01; 69(2):370-80. PubMed ID: 16380103
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identifying a role of the actin capping protein CapZ in β-adrenergic receptor signalling.
    Gaikis L, Stewart D, Johnson R, Pyle WG.
    Acta Physiol (Oxf); 2013 Jan 01; 207(1):173-82. PubMed ID: 22882973
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
    O'Leary TS, Snyder J, Sadayappan S, Day SM, Previs MJ.
    J Mol Cell Cardiol; 2019 Feb 01; 127():165-173. PubMed ID: 30550750
    [Abstract] [Full Text] [Related]

  • 15. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
    Fraysse B, Weinberger F, Bardswell SC, Cuello F, Vignier N, Geertz B, Starbatty J, Krämer E, Coirault C, Eschenhagen T, Kentish JC, Avkiran M, Carrier L.
    J Mol Cell Cardiol; 2012 Jun 01; 52(6):1299-307. PubMed ID: 22465693
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.
    Najafi A, Schlossarek S, van Deel ED, van den Heuvel N, Güçlü A, Goebel M, Kuster DW, Carrier L, van der Velden J.
    Pflugers Arch; 2015 Jun 01; 467(6):1303-17. PubMed ID: 25010737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.